Popular Articles
Teeth Whitening Products

Merz Pharmaceuticals Announce Three Studies Of NT-201 - (Botulinum Neurotoxin Type A Free From Complexing Proteins)
Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented at the Movement Disorder Society (MDS) 13th Annual International Congress in Paris, France. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future.
generic viagra online
Better Access To Info And Dialogue With HCPs On Sexual Issues For Rheumatology Patients
Patients with rheumatic diseases want more information and better communication with healthcare professionals on the sexual issues related to their conditions, according to the results of a new study presented recently at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark.
News of the day
Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) In Head-to-Head DURATION-3 Study
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus® (insulin glargine). Patients randomized to exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months, of 1.5 percentage points from baseline, compared to a reduction of 1.3 percentage points for Lantus after completing 26 weeks of treatment. At the end of the study, patients treated with exenatide once weekly achieved a mean A1C of 6.8 percent compared with a mean A1C of 7.0 percent in those treated with Lantus. Treatment with exenatide once weekly also produced a statistically significant difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean weight gain of 3.1 pounds for Lantus, a difference of 8.9 pounds between the treatments.
Public Health

Cancer Risk In Delaying Sex Assignment Surgery

An editorial and a case report on Disorders of Sexual Development (DSD) in the Medical Journal of Australia highlight the need for early diagnosis and effective risk management in these rare but potentially life threatening cases. DSD describes conditions in which patients are born with ambiguous genitalia; DSD were previously described by terms such as "intersex", "hermaphroditism" and "testicular feminisation". In the editorial, endocrinologists from Melbourne"s Royal Children"s Hospital, Dr Garry Warne and Dr Jacqueline Hewitt, discuss the sometimes contentious management of the disorder, and call for the preparation of separate risk management strategies for individual patients. "International debate continues about the ethics of performing genital surgery on affected infants and children," Dr Warne said. "The option to assign a gender but postpone surgery until the child is able to give consent has been strongly advocated in some quarters, but hasn"t gained wide acceptance because of concerns that children might suffer psychological harm if left with ambiguous genitalia. "Another dilemma in delaying sex-assignment surgery is the increased risk of gonadal malignancy. what has largely been missing from the debate is recognition that surgery forms a necessary part of the risk management strategy for preventing gonadal malignancy." Gonadal malignancy proved fatal in a case detailed in the MJA by Dr Jim Parker (et al) from the University of Western Sydney. The case was of a 59 year old man who presented with previously undiagnosed DSD. Internal investigations for a related complaint revealed a normally formed uterus and an abdominal gonad with an advanced malignancy. The uterus and gonad were surgically removed, and the patient was treated postoperatively with chemotherapy, but died 18 months later. Dr Warne said the tragic case highlighted the need for accurate diagnosis and early monitoring and care from a multidisciplinary team. "The means for accurate diagnosis are improving with the development of microarray technology that offers an exciting and promising advance in identifying genetic mutations," Dr Warne said. Medical Journal of Australia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):